JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares S&P 500 Value ETF
IVE
|
+$2.05B |
| 2 |
iShares S&P 500 Growth ETF
IVW
|
+$1.92B |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.13B |
| 4 |
iShares Russell 1000 Value ETF
IWD
|
+$1.1B |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Japan ETF
BBJP
|
+$1.24B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$1.12B |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$989M |
| 4 |
Microsoft
MSFT
|
+$973M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$931M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.54% |
| 2 | Technology | 14.97% |
| 3 | Healthcare | 10.91% |
| 4 | Financials | 10.87% |
| 5 | Consumer Discretionary | 8.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NXGN
3301
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $910K | ﹤0.01% |
87,172
-797
| -0.9% | -$10.3K |
2016 Q4
13 quarters
|
|
3302
Resources Connection
RGP
$129M
| $908K | ﹤0.01% |
82,832
-71,304
| -46% | -$970K |
2013 Q2
27 quarters
|
|
3303
Aquestive Therapeutics
AQST
$576M
| $907K | ﹤0.01% |
413,962
+95,381
| +30% | +$362K |
2018 Q3
6 quarters
|
|
|
APTS
3304
DELISTED
Preferred Apartment Communities, Inc.
APTS
| $907K | ﹤0.01% |
126,327
-4,254
| -3% | -$46.2K |
2016 Q4
13 quarters
|
|
3305
NovaGold Resources
NG
$2.93B
| $903K | ﹤0.01% |
122,415
-3,891
| -3% | -$33.3K |
2016 Q3
14 quarters
|
|
|
KE
3306
Kimball Electronics
KE
$687M
| $900K | ﹤0.01% |
82,361
-751
| -0.9% | -$11.2K |
2014 Q4
21 quarters
|
|
3307
Vanguard Energy ETF
VDE
$10.8B
| $900K | ﹤0.01% |
23,536
-14,141
| -38% | -$897K |
2015 Q3
18 quarters
|
|
3308
Artesian Resources
ARTNA
$348M
| $899K | ﹤0.01% |
24,069
-4,887
| -17% | -$179K |
2013 Q2
27 quarters
|
|
3309
CALL
Moderna
MRNA
$77.1B
| $899K | ﹤0.01% |
+30,000
| New | +$690K |
2020 Q1
0 quarters
|
|
|
3310
PUT
Moderna
MRNA
$77.1B
| $899K | ﹤0.01% |
+30,000
| New | +$690K |
2020 Q1
0 quarters
|
|
|
RMAX
3311
DELISTED
RE/MAX Holdings
RMAX
| $899K | ﹤0.01% |
40,982
+35,123
| +599% | +$1.14M |
2013 Q4
25 quarters
|
|
|
CBMG
3312
DELISTED
Cellular Biomedicine Group, Inc.
CBMG
| $896K | ﹤0.01% |
56,702
+34,148
| +151% | +$552K |
2018 Q2
7 quarters
|
|
3313
PUT
Viatris
VTRS
$20.3B
| $895K | ﹤0.01% |
60,000
-180,500
| -75% | -$3.46M |
2019 Q1
4 quarters
|
|
3314
Northrim BanCorp
NRIM
$552M
| $894K | ﹤0.01% |
132,540
-3,884
| -3% | -$33.5K |
2017 Q4
9 quarters
|
|
|
CLDR
3315
DELISTED
Cloudera, Inc.
CLDR
| $894K | ﹤0.01% |
113,637
-1,038,117
| -90% | -$10.1M |
2017 Q2
11 quarters
|
|
3316
Invesco S&P 500 Equal Weight Health Care ETF
RSPH
$875M
| $891K | ﹤0.01% |
47,110
-30,000
| -39% | -$635K |
2018 Q3
6 quarters
|
|
3317
WisdomTree
WT
$3.7B
| $891K | ﹤0.01% |
382,398
+306,993
| +407% | +$1.19M |
2014 Q2
23 quarters
|
|
3318
CALL
Duke Energy
DUK
$89.5B
| $890K | ﹤0.01% |
11,000
-368,500
| -97% | -$33.8M |
2017 Q1
12 quarters
|
|
3319
Marcus Corp
MCS
$823M
| $890K | ﹤0.01% |
72,311
+7,038
| +11% | +$177K |
2016 Q1
16 quarters
|
|
3320
Vitamin Cottage Natural Grocers
NGVC
$685M
| $887K | ﹤0.01% |
104,240
-16,673
| -14% | -$143K |
2017 Q3
10 quarters
|
|
|
EXTN
3321
DELISTED
Exterran Corporation
EXTN
| $887K | ﹤0.01% |
184,616
+55,153
| +43% | +$331K |
2015 Q4
17 quarters
|
|
3322
Invesco FTSE RAFI US 1000 ETF
PRF
$9.96B
| $885K | ﹤0.01% |
47,900
+47,150
| +6,287% | +$1.09M |
2018 Q3
6 quarters
|
|
|
FLOW
3323
DELISTED
SPX FLOW, Inc.
FLOW
| $884K | ﹤0.01% |
31,099
+2,055
| +7% | +$78.3K |
2015 Q3
18 quarters
|
|
3324
CALL
Vale
VALE
$60.4B
| $880K | ﹤0.01% |
106,100
-1,063,100
| -91% | -$11.6M |
2017 Q1
12 quarters
|
|
|
SIX
3325
CALL
DELISTED
Six Flags Entertainment Corp.
SIX
| $878K | ﹤0.01% |
+70,000
| New | +$2.08M |
2020 Q1
0 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2020 Portfolio in Review
As of Q1 2020, JP Morgan Chase held 6,012 positions worth $426B, down 21% from $536B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase deployed $14B of net new capital in Q1 2020, opening 362 new positions and adding to 2,382 existing holdings. Its largest new stake was NextEra Energy, Inc. 5.279% Corporate Units: 1,245,017 shares worth $54.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, down from 28% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was JPMorgan BetaBuilders Japan ETF, an estimated $1.24B trimmed.
- JP Morgan Chase's largest Q1 2020 buy was NextEra Energy, Inc. 5.279% Corporate Units: 1,245,017 shares worth $54.9M.
- JP Morgan Chase added most to iShares S&P 500 Value ETF in Q1 2020, an estimated $2.05B increase.
- JP Morgan Chase's biggest Q1 2020 reduction was JPMorgan BetaBuilders Japan ETF, cutting an estimated $1.24B.
- JP Morgan Chase fully exited Liberty Property Trust in Q1 2020, selling an estimated $264M.
- JP Morgan Chase's ten largest holdings make up 18% of its $426B portfolio in Q1 2020.
- JP Morgan Chase opened 362 new positions and closed 692 in Q1 2020.
- JP Morgan Chase's portfolio value fell 21% quarter-over-quarter to $426B.
Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.